GlassScriptPhysician profile
David R Fermin
NPI 1447442215
$105,433.89
in general payments reported to CMS, 2019-2025
16 companies · $39K in 2025
The $39K reported for 2025 was more than what 90% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $242 · 2020: $5,370 · 2021: $11K · 2022: $2,531 · 2023: $33K · 2024: $14K · 2025: $39K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Consulting Fee: $9,770 · Travel and Lodging: $3,673 · Food and Beverage: $2,397 · Education: $59.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,076.00 |
| Consulting Fee | $9,770.00 |
| Travel and Lodging | $3,673.40 |
| Food and Beverage | $2,397.42 |
| Education | $59.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $90,249.50 | 2021-2025 | Camzyos, Eliquis |
| Pfizer INC. | $7,999.57 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $5,905.48 | 2020-2025 | Amvuttra, Onpattro |
| Abbott Laboratories | $689.27 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.16 | 2019-2022 | |
| Novo Nordisk INC | $78.21 | 2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $71.17 | 2019-2025 | Lifevest |
| Janssen Pharmaceuticals, INC | $61.75 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $50.97 | 2021-2022 | |
| Medtronic Vascular, INC. | $46.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $33.41 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $30.30 | 2019-2020 | |
| Akcea Therapeutics, INC. | $21.37 | 2019 | |
| Amgen INC. | $19.42 | 2023 | Repatha |
| Insmed, INC. | $17.29 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fermin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.